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SUMMARY
During antibody affinity maturation, germinal center (GC) B cells cycle between affinity-driven 
selection in the light zone (LZ) and proliferation and somatic hypermutation in the dark zone 
(DZ). Although selection of GC B cells is triggered by antigen-dependent signals delivered in the 
LZ, DZ proliferation occurs in the absence of such signals. We show that positive selection 
triggered by T cell help activates the mechanistic target of rapamycin complex 1 (mTORC1), 
which promotes the anabolic program that supports DZ proliferation. Blocking mTORC1 prior to 
growth prevented clonal expansion, whereas blockade after cells reached peak size had little to no 
effect. Conversely, constitutively active mTORC1 led to DZ enrichment but loss of 
competitiveness and impaired affinity maturation. Thus, mTORC1 activation is required for 
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fueling B cells prior to DZ proliferation rather than for allowing cell cycle progression itself, and 
must be regulated dynamically during cyclic re-entry to ensure efficient affinity-based selection.
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Introduction
Germinal centers (GCs) are the primary site of affinity maturation, the process whereby the 
affinity of serum antibodies increases with time after immunization (Eisen and Siskind, 
1964). Affinity maturation relies on somatic mutation of immunoglobulin genes followed by 
positive selection—defined here as re-entry from light zone (LZ) to dark zone (DZ) followed 
by clonal expansion—of GC B cells that have attained improved affinity for antigen (Allen 
et al., 2007; MacLennan, 1994; Mesin et al., 2016; Victora and Nussenzweig, 2012). A key 
feature of this expansion is the ability of selected B cells to undergo sustained and rapid 
proliferation in the DZ in the apparent absence of further antigen-dependent signals. This 
can be readily observed when selection is artificially induced by forcing GC B cell-T 
follicular helper (Tfh) cell interactions (Gitlin et al., 2015; Gitlin et al., 2014; Victora et al., 
2010), but is also likely to be at the origin of the “clonal bursts” that can lead to radical loss 
of clonal diversity in GCs under unmanipulated conditions (Tas et al., 2016). The finding 
that the number of B cell divisions in the DZ is proportional to the strength of the signals 
from Tfh cells in the LZ (Gitlin et al., 2014) suggests the existence of B cell-intrinsic 
molecular circuits that link positive selection in the LZ to sustained DZ proliferation and 
determine the timing of the return of these cells to the LZ (Bannard et al., 2013). Previous 
work by us and others has shown that c-Myc, a key regulator of cell cycle and the driver 
oncogene in Burkitt lymphoma, is induced in GC B cells upon positive selection in the LZ 
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(Calado et al., 2012; Dominguez-Sola et al., 2012), and that its activity is prolonged upon 
migration of selected cells to the DZ by c-Myc-dependent induction of the related 
transcription factor AP4 (Chou et al., 2016). However, c-Myc expression alone is 
insufficient to drive a robust proliferative program in B cells (Sander et al., 2012), and 
therefore additional pathways are likely required to link positive selection in the LZ to 
sustained cell cycling in the DZ.
The mechanistic target of rapamycin (mTOR) is a serine-threonine kinase critically involved 
in the control of anabolism and metabolic reprogramming in immune cells (Powell et al., 
2012). A range of stimuli—including energy, amino acids, oxygen, glucose, growth factors, 
and immune signals—activate mTOR complex 1 (mTORC1), which in turn activates 
multiple anabolic programs that lead to cell growth (Laplante and Sabatini, 2012). In the 
immune system, mTORC1 has been linked to T cell differentiation, tolerance, anergy, and 
migration (Araki et al., 2009; Sinclair et al., 2008; Zeng et al., 2013; Zheng et al., 2007), as 
well as to B cell differentiation and antibody production (Jones et al., 2016; Limon et al., 
2014; Lin et al., 2015; Omori et al., 2006). However, fine dissection of the specific role of 
mTORC1 in GC selection has been difficult to achieve, because genetic or pharmacological 
inhibition of this pathway in mice normally leads to GC dissolution (Jones et al., 2016; 
Keating et al., 2013; Zhang et al., 2013). Given that GC B cells cycle asynchronously 
between proliferation in the DZ and selection in the LZ, such approaches do not allow for an 
analysis of the specific requirements for mTORC1 at different stages of positive selection.
Here, we have used an in vivo model to target and synchronize positive selection to a 
predefined subset of GC B cells, which allowed us to investigate the specific role of 
mTORC1 in this process in a time-resolved manner. We found that mTORC1 activation was 
required early after positive selection to trigger the anabolic cell growth that sustained 
extensive cell division in the DZ, but became largely dispensable once this proliferative 
program had been initiated. We thus propose a model in which GC B cell anabolism 
triggered by mTORC1 links the strength of antigen-dependent selection in the LZ to the 
extent of clonal expansion in the DZ.
Results
Positive selection of GC B cells activates mTORC1 in a CD40-dependent manner
To investigate the molecular pathways associated with GC positive selection in vivo, we 
used a previously developed protocol in which selection of a traceable subpopulation of GC 
B cells can be triggered by targeted delivery of antigen via the surface lectin DEC-205 
(encoded by the gene Ly75). This protocol forces targeted GC B cells to interact with Tfh 
cells, triggering LZ to DZ migration and extensive cell proliferation (Victora et al., 2010); 
positive selection then proceeds in a synchronous manner, and can be followed over time. In 
brief, we co-transfer into ovalbumin (OVA)-primed recipient mice two populations of naïve 
B cells, a majority population (85%) which is deficient for DEC-205 (Ly75−/−) (Inaba et al., 
1995) and a minority population (15%) which is Ly75+/+ (Fig.1A). Both Ly75+/+ and 
Ly75−/− populations express a B1-8hi variant of the Ig heavy chain that, when paired to an 
Igλ light chain, bind with high affinity to 4-hydroxy-3-nitro-phenylacetyl (NP) (Shih et al., 
2002). Boosting with NP-OVA generates GCs that contain B1-8hi B cells at a proportion 
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similar to that of the input population (85% Ly75−/−/15% Ly75+/+), which are helped by 
OVA-specific Tfh cells. Subsequent injection of an antibody to DEC-205 recombinantly 
fused to OVA (DEC-OVA) ensures delivery of the T cell antigen to Ly75+/+ GC B cells only, 
strongly skewing T cell help towards these cells and triggering positive selection (Victora et 
al., 2010).
To determine which transcriptional programs are induced by positive selection in this model, 
we isolated and sequenced mRNA from Ly75+/+ and Ly75−/− LZ B cells 12 h after DEC-
OVA injection, a time point when Ly75+/+ cells were enriched in the LZ, strongly interacting 
with Tfh cells (Shulman et al., 2014). As expected from our previous findings (Dominguez-
Sola et al., 2012), Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) 
revealed strong upregulation of gene signatures associated with the cellular response to c-
Myc (Schuhmacher et al., 2001; Sun et al., 2017; Zeller et al., 2003) (Fig. S1A). Of note, 
comparison with our own previously published signature of genes upregulated in GC B cells 
expressing c-Myc, which marks B cells currently undergoing positive selection under 
steady-state (Dominguez-Sola et al., 2012), showed substantial coincidence between the two 
programs (Fig. S1B), further supporting the notion that Tfh cells are bona fide drivers of GC 
positive selection.
GSEA analysis also showed strong upregulation in Ly75+/+ B cells of signatures related to 
the activation of mTORC1 (Fig. 1B). These included genes downregulated in a human B cell 
lymphoma line (BJAB) by treatment with the mTORC1 inhibitor rapamycin or by removal 
of leucine from tissue culture media (which also inhibits mTORC1) (Peng et al., 2002). 
Thus, in addition to c-Myc, GC positive selection also appears to involve activation of 
mTORC1. To verify this directly, we immunized mice with NP conjugated to keyhole limpet 
hemocyanin (KLH) in alum and stained histological sections of draining lymph nodes 14 
days later for the phosphorylation of ribosomal protein S6 on serines 235 and 236 (targets of 
S6 kinase, itself a target of mTORC1). Although most GC cells showed increased S6 
phosphorylation when compared to naïve B cells, cells with the highest amounts of 
phospho-S6 were detected predominantly in the LZ, with marked enrichment among c-Myc-
expressing cells (Fig. 1C and S1C). This enrichment was confirmed by flow cytometry using 
a reporter mouse strain carrying a GFP-Myc fusion protein (Huang et al., 2008) (Fig. 1D). 
Thus, mTORC1 activity is upregulated specifically in LZ cells during positive selection, and 
concomitantly with activation of c-Myc.
To investigate the kinetics of mTORC1 induction, we forced B cell-Tfh cell interaction with 
DEC-OVA as in Fig. 1A and measured the extent of S6 phosphorylation over time (Fig. 1E–
F). DEC-OVA induced robust phosphorylation of S6 as early as 12 h post-treatment, when 
targeted cells are found predominantly in the LZ interacting with Tfh cells (Shulman et al., 
2014). Increased phosphorylation persisted up to at least 36 h after DEC-OVA, by which 
time most selected cells have already migrated to the DZ (Victora et al., 2010), and returned 
to steady-state by 72 h post-treatment. Phosphorylation of S6 protein was less pronounced 
when mice were given a lower dose of DEC-OVA or when the proportion of Ly75+/+ B cells 
was increased (which increases competition among Ly75+/+ B cells for Tfh cell help) (Fig 
1G–H). Thus, GC B cells respond dynamically to the availability of T cell help by activating 
the mTORC1 pathway to different degrees. Mechanistically, injection of an antagonist 
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antibody to CD40L (MR-1) prior to DEC-OVA fully prevented the increase in S6 
phosphorylation (Fig. 1I–J), and conversely, treatment of mice bearing GCs induced by 
immunization with KLH in alum with a CD40 agonist antibody (FGK4.5) induced strong S6 
phosphorylation in GC B cells (Fig. S1D–E). Thus, CD40 ligation is both necessary and 
sufficient for activation of the mTORC1 pathway in GC B cells during positive selection. We 
conclude that CD40-mediated interaction with Tfh cells leads to dose-dependent activation 
of the mTORC1 pathway in LZ B cells, which then decreases progressively as these cells 
migrate to the DZ and undergo multiple rounds of proliferation.
mTORC1 activation in positively selected GC B cells promotes ribosome biogenesis and 
cell growth
The best-characterized role of mTORC1 is to drive cellular growth by inducing anabolism 
and ribosomal biogenesis (Laplante and Sabatini, 2012). Accordingly, Ly75+/+ GC B cells 
showed increases in in vivo glucose uptake, (ds)RNA content (which consists mostly of 
ribosomal RNA), and forward scatter (FSC, a surrogate for cell size) in response to DEC-
OVA, all of which were at least partly abrogated by treatment with rapamycin (Fig 2A–D). 
Detailed kinetic analysis (Fig. 2E–H and S2) showed that FSC and dsRNA content peak 
simultaneously at 36 h after DEC-OVA treatment, which roughly coincided with the onset of 
the proliferative burst that positively selected cells undergo in the DZ (shaded area in Fig. 
2E–H). Concomitant measurement of S6 phosphorylation showed that the rise in mTORC1 
activity preceded the increase in FSC and dsRNA content by approximately 12 h, consistent 
with a role for mTORC1 in driving GC B cell growth prior to proliferation. All three 
parameters decreased during the strong proliferative phase in which the Ly75+/+ cell 
population rapidly expanded in the DZ (shaded gray area in Fig. 2E–H), returning to 
baseline as these cells re-entered the LZ between 72 and 96 h post-treatment (Fig. 2H). 
Thus, mTORC1 activation triggers an anabolic program that involves increased glucose 
uptake, ribosomal biogenesis, and cell growth in positively selected B cells. Of note, the 
peak of this program preceded, rather than being concomitant with, the proliferative burst 
that takes place subsequently in the DZ.
The coincidence in time between the decrease in cell size and return to steady-state DZ/LZ 
ratio (Fig. 2E and H) led us to hypothesize that the timing of the return to the LZ after the 
DZ proliferative phase may be related to loss of cellular biomass. This predicts that 
positively selected B cells returning from DZ to LZ would be on average smaller than those 
being retained in the DZ. To test this, we triggered positive selection with DEC-OVA using 
B1-8hi cells that express a photoactivatable (PA)-GFP transgene (Victora et al., 2010), and 
can thus be photolabeled in vivo based on their anatomical position (Fig. 3A). At 48 h after 
DEC-OVA, when most positively selected cells are large and actively proliferating in the DZ 
(where they remain for approximately another 24–48 h), we photoactivated PA-GFP+ cells 
in the DZ and then analyzed lymph nodes by flow cytometry 8 h later. This strategy allowed 
us to identify “early emigrant” B cells, which left the DZ for the LZ (and acquired LZ 
surface markers) earlier than expected (Fig. 3B–C). Early emigrants thus identified were on 
average smaller than the cells that remained in the DZ over this 8 h period, and were more 
similar in size to the counterselected Ly75−/− cells from the same LN (dotted lines in Fig. 
3D). Thus, the end of the proliferative phase that positively selected GC B cells undergo in 
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the DZ correlates with smaller cell size, thus linking return from DZ to LZ to the anabolic 
state of the cell.
mTORC1 is required for LZ to DZ migration and cell growth prior to clonal expansion, but 
not for cell cycle progression
Our kinetic data suggested a scenario in which mTORC1 allows selected LZ cells to reach 
the size and anabolic capacity necessary to sustain multiple division cycles in the DZ (Fig. 2 
and 4A). This hypothesis predicts that selected cells would require mTORC1 activity only 
during the period of growth preceding the proliferative burst, but that active mTORC1 would 
be dispensable after the cells have reached peak size. To test this, we inhibited mTORC1 
activity by injection of rapamycin 12, 24, or 36 h after forcing positive selection of Ly75+/+ 
cells with DEC-OVA (Fig 4A–B). These time points correspond to suppressing mTORC1 
before (12 h), midway through (24 h), and after (36 h) the period of cell growth, but in all 
cases before any substantial proliferation has taken place. Lymph nodes were harvested and 
analyzed by flow cytometry at 48 h after DEC-OVA treatment. Treatment with rapamycin at 
12, 24 and 36 h after DEC-OVA injection equally suppressed phosphorylation of S6 (Fig. 
S3A–B), but it only effectively prevented the expansion of the Ly75+/+ cells when 
administered 12 h after DEC-OVA (Fig. 4C). Notably, rapamycin had little effect on 
subsequent cell proliferation when injected after the culmination of the growth phase at 36 h 
after DEC-OVA treatment, even when cells were analyzed at 60 h after DEC-OVA (24 h 
post-rapamycin) (Fig. 4C–D). Even more pronounced was the effect of rapamycin on the 
ability of positively selected LZ B cells to transition to and maintain a DZ program (Fig. 
4E–F). Again, this effect was especially strong when rapamycin was administered 12 h after 
DEC-OVA, but was still noticeable when the drug was administered at 36 h, a point at which 
most LZ to DZ transition has already occurred. LZ entrapment of GC B cells upon 
rapamycin treatment was associated with failure to upregulate Foxo1, an essential regulator 
of the DZ phenotype (Dominguez-Sola et al., 2015; Sander et al., 2015) (Fig. 4G).
Despite its effect on clonal expansion when administered prior to cell growth, flow 
cytometric measurement of DNA content (Fig. 4H–I) and rate of S phase entry (Gitlin et al., 
2014) (Fig. 4J) showed that rapamycin treatment did not cause cell cycle arrest in Ly75+/+ B 
cells, irrespective of time of administration. Consistent with these observations, global gene 
expression analysis showed that rapamycin had only a mild effect on the ability of DEC-
OVA to drive the upregulation of gene signatures associated with c-Myc and its proliferative 
program, although it strongly suppressed upregulation of mTORC1-related signatures (Fig. 
S3C). Similarly, treatment with rapamycin only slightly decreased the expression of GFP-c-
Myc in steady-state GC B cells (Fig. S3D). Thus, the effects of rapamycin are unlikely to be 
fully explained by functional cross-talk between mTORC1 and c-Myc. Overall, we conclude 
that the essential roles of the rapamycin-sensitive arm of the mTORC1 pathway in GC 
selection are to trigger the anabolic program that precedes proliferation and to regulate LZ to 
DZ positioning, rather than to directly regulate cell cycle progression.
Unlike traditional genetic ablation approaches, using rapamycin to probe the function of 
mTORC1 in vivo allows tight kinetic regulation, which is crucial when dealing with highly 
dynamic reactions such as the GC. A key caveat to the use of chemical inhibitors in vivo, 
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however, is the lack of cellular specificity—that is, systemic administration of rapamycin 
will presumably inhibit mTORC1 function throughout the organism, and therefore direct 
effects on B cells cannot be discerned from indirect effects via other cell types. To address 
this, we developed a chemical-genetic approach to target rapamycin resistance specifically to 
GC B cells in vivo. We used CRISPR/Cas9 genomic editing in zygotes (Wang et al., 2013; 
Yang et al., 2013a) to introduce a point mutation into exon 45 of the Mtor gene (F2108L) 
that confers resistance to rapamycin (Figs. 5A and S4A–B). This mutation, identified in a 
human thyroid cancer resistant to Everolimus (a rapamycin analog), confers drug resistance 
in a dominant fashion by preventing the docking of the rapamycin-FKBP12 complex to 
mTOR (Wagle et al., 2014). Accordingly, cultured tail fibroblasts from the MtorF2108L/+ 
founder mouse were resistant to rapamycin treatment in vitro (Fig. 5B). To test resistance in 
vivo, we triggered mTORC1 activation by fasting and then refeeding mice in the presence or 
absence of rapamycin (Efeyan et al., 2014). While rapamycin abrogated feeding-induced 
phosphorylation of mTORC1 targets in liver and cardiac and skeletal (gastrocnemius) 
muscles of Mtor+/+ mice, liver and cardiac muscle of MtorF2108L/+ mice were fully resistant 
to the drug, with the gastrocnemius muscle showing partial resistance (Fig. S4C–E). Of note, 
the MtorF2108L allele behaved as a mildly hypomorphic allele in gastrocnemius muscle but 
not in cardiac muscle or liver, correlating with the intrinsic mTORC1 activity in each organ.
To address the cell-specific effect of rapamycin in GC B cells, we performed experiments 
analogous to those described in Fig. 4 but in which rapamycin-sensitive (Mtor+/+) B1-8hi B 
cells were transferred into rapamycin-resistant (MtorF2108L/F2108L) hosts (Figs. 5C and 
S5A). As expected, rapamycin treatment led to robust loss of DEC-OVA-induced S6 
phosphorylation in the transferred B1-8hi GC B cells, but not in the minor population of 
host-derived B cells also present in B1-8hi GCs (Fig. 5D and S5B–C). As with wild-type 
hosts (Figs. 2 and 4), rapamycin prevented DEC-OVA driven B1-8hi cell growth (Fig. S5D), 
clonal expansion (Fig. 5E), and accumulation in the DZ (Fig. 5F), consistent with a B cell-
intrinsic requirement for mTORC1. Conversely, when selection of rapamycin-resistant 
Ly75+/+ B1-8hi B cells was forced within rapamycin-sensitive hosts (Fig. 5G–H and S5E–F), 
presence of the MtorF2108L allele rescued the effects of rapamycin on all of these parameters 
(Fig. 5I–J and S5G). Of note, although rapamycin inhibited S6 phosphorylation in Tfh cells 
in Mtor+/+ hosts but not in MtorF2108L/F2108L hosts (Fig. 5K), the effectiveness of rapamycin 
depended exclusively on the genotype of the transferred GC B cells. Thus, although 
mTORC1 plays a clear role in Tfh cell differentiation (Zeng et al., 2016), our results suggest 
that inhibiting this pathway in mature Tfh cells has little measurable effect on their short-
term ability to promote GC B cell selection. We conclude that GC B cell growth, 
proliferative expansion and LZ to DZ transition require cell-intrinsic activity of mTORC1.
Deregulated mTORC1 activation decreases GC B cell competitiveness and impairs affinity 
maturation
We next sought to determine whether mTORC1 activation alone is sufficient to favor 
positive selection of GC B cells, or whether, conversely, constitutively high mTORC1 
activity has an adverse effect on GC B cell competitiveness. To this end, we generated a 
gain-of-function model in which mice bearing a loxP-flanked allele of the mTORC1 
inhibitor Tsc1 (Kwiatkowski et al., 2002) were crossed to strains expressing Cre 
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recombinase from the Aicda (AID) locus (Robbiani et al., 2009) and to the genetically 
targeted B1-8hi Igh allele. Cre-driven recombination in this model leads to strong 
constitutive mTORC1 activity in GC B cells specifically. We adoptively transferred a 1:1 
mixture of Aicdacre/+.Tsc1fl/fl B1-8hi and Aicdacre/+.Tsc1+/+ B1-8hi B cells into WT hosts, 
which we then immunized with NP-OVA (Fig. 6A). As expected, GC B cells on the 
Aicdacre/+.Tsc1fl/fl background showed strong mTORC1 activation, as determined by S6 
phosphorylation (Fig. 6B). Aicdacre/+.Tsc1fl/fl GC B cells were also enriched in cells with 
DZ phenotype, confirming a cell-intrinsic role for mTORC1 in regulating the LZ to DZ 
transition (Fig. 6C–D). In spite of this enrichment, the proportion of Aicdacre/+.Tsc1fl/fl 
B1-8hi GC B cells decreased progressively over time (Fig. 6E), indicating that unrestrained 
mTORC1 activity leads to a competitive disadvantage in GC selection. To ensure that lack of 
competitiveness was not a result of the supra-physiological activation of mTOR driven by 
deletion of Tsc1, we performed a similar set of experiments using mice engineered to 
express a constitutively active allele of the RagA (Rraga) GTPase, RragaQ66L (referred to 
hereafter as RragaGTP) (Efeyan et al., 2013). Presence of this allele leads to loss of amino 
acid regulation of mTORC1, and only mild over-activation of this pathway. We bred the 
RragaGTP allele to the B1-8i Igh (Sonoda et al., 1997), which also confers binding to NP 
when paired to an Igλ light chain, but with lower affinity than the B1-8hi allele [due to 
absence of an affinity-enhancing W to L mutation in position 33 (W33L) (Allen et al., 
1988)]. Because RragaGTP/GTP mice die perinatally (Efeyan et al., 2013), we generated fetal 
liver chimeras, and used these as B cell donors for adoptive transfer at 1:1 ratio with B1-8i 
cells with normal mTORC1 activity (Fig. 6F). As with TSC1 deficiency, RragaGTP/GTP GC 
B cells showed higher than normal mTOR activity (Fig. 6G) and were moderately enriched 
in DZ phenotype (Fig. 6H–I). Again, RragaGTP/GTP B cells were strongly outcompeted in 
GCs over time (Fig. 6J). Thus, although mTORC1 activation is essential for positive 
selection of GC B cells (Fig. 4), and can favor the acquisition of a DZ phenotype normally 
associated with proliferation in a cell-autonomous manner, constitutive activation of this 
pathway does not on its own increase GC B cell competitiveness, and is instead detrimental 
for GC selection.
To investigate whether constitutively active mTORC1 affects the ability of B cells to 
undergo affinity maturation, we immunized mTORC1 gain-of-function mice with NP-OVA 
in alum and measured the increase in titers of circulating total (NP24-binding) and high-
affinity (NP2-binding) antibodies over a 28-day period by ELISA. To avoid any potential 
effects related to preferential selection of GC B cells that failed to recombine the floxed 
allele in Tsc1fl/fl. Aicdacre/+ mice, we generated Cd79acre/+.Tsc1fl/fl mice, in which 
recombination is triggered in a large fraction of B cells during development (Hobeika et al., 
2006), making presence of unrecombined B cells in GCs less likely. Although 
Cd79acre/+.Tsc1fl/fl mice produced NP-specific antibodies that were comparable in titer to 
those of Cd79acre/+.Tsc1+/+ littermates (Fig. 7A), affinity maturation was almost entirely 
abrogated in these mice (Fig. 7B). Analogous experiments using the RragaGTP allele 
produced comparable results. Whereas global anti-NP titers upon immunization of 
hematopoietic chimeras made from RragaGTP/GTP or Rraga+/+ fetal livers were similar (Fig. 
7C), RragaGTP/GTP chimeras again were deficient in affinity maturation (Fig. 7D), albeit to a 
lesser extent than Cd79acre/+.Tsc1fl/fl mice. Because mTORC1 hyperactivation in chimeric 
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mice is not B cell-specific, we performed additional experiments using adoptive transfer of 
B1-8i RragaGTP/GTP or B1-8i Rraga+/+ B cells from fetal liver chimeras into WT mice, 
which we then immunized subcutaneously with NP-OVA in alum. Igh sequencing of single-
sorted GC B cells from draining lymph nodes of recipient mice at day 12 after immunization 
showed that, although somatic mutations accumulated to a similar extent in both cases (Fig. 
7E), RragaGTP/GTP GC B cells that acquired the affinity-enhancing W33L mutation were 
enriched to a significantly lower extent than their Rraga+/+ counterparts (Fig. 7F). We 
conclude that uncoupling mTORC1 activity from affinity-dependent selection impairs the 
accumulation of high-affinity B cells in GCs as well as in the antibody secreting cell 
compartment.
Discussion
B cells selected in the GC LZ activate pathways that act in concert to enable their rapid 
clonal expansion in the DZ. We now show that, in addition to activating c-Myc and other 
transcriptional regulators, T cell help also drives activation of the mTORC1 pathway in GC 
B cells, promoting a phase of anabolic growth that precedes and sustains the successive 
cycles of DZ proliferation. mTORC1 activity in positively selected GC B cells can be 
modulated by varying either the dose of DEC-OVA or the ratio of Ly75+/+ to Ly75−/− B 
cells, which alters the degree of competition for Tfh cells among this population. Because 
extent of T cell help also defines the magnitude of the ensuing proliferative burst (Gitlin et 
al., 2014), our findings point to a quantitative link between T cell help, mTORC1 activation, 
and the number of division cycles a GC B cell can withstand following LZ to DZ transition.
Injection of the mTORC1 inhibitor rapamycin prior to cell growth markedly impaired the 
extent to which B cells accumulate upon forced positive selection. This effect occurred 
without measurable impact on cell cycle progression, regardless of the timing of rapamycin 
administration. These results indicate that the primary role of mTORC1 in GC selection is to 
ensure that B cells have sufficient biomass and growth potential to support rapid and 
repeated division cycles, rather than to directly control cell cycling. These data are in 
contrast to the notion that mTORC1 directly drives cell cycle progression (Aagaard-Tillery 
and Jelinek, 1994; Fingar et al., 2004), but are consistent with an anabolic role for mTORC1 
in cell division (Barbet et al., 1996; Dowling et al., 2010). Thus, while anabolism and 
proliferation are necessarily co-regulated and tend to occur simultaneously, in the process of 
GC B cell selection these two are spatially and temporally segregated, and depend on 
mTORC1 to different extents.
mTORC1 also has a marked effect on the DZ to LZ ratio of GC B cells that appears to be 
stronger than, and independent of, its effects on population expansion. Rapamycin treatment 
reproducibly decreased the proportion of B cells in the DZ even in conditions where 
expansion is unaffected, and conversely, mTORC1 hyperactivation led to accumulation of B 
cells in the DZ without increasing proliferation. This finding may be explained by an 
indirect effect of mTORC1 on the activity of Foxo1, a key regulator of the DZ phenotype 
(Dominguez-Sola et al., 2015; Sander et al., 2015). In agreement, our data show that 
rapamycin treatment prevents upregulation of Foxo1 upon induction of positive selection by 
DEC-OVA. We speculate that failure to upregulate Foxo1 may prevent establishment of the 
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DZ program without affecting cell cycle. Such uncoupling is similar to that observed upon 
specific deletion of Foxo1 in GC B cells (Dominguez-Sola et al., 2015; Sander et al., 2015).
The full extent to which c-Myc and mTORC1 synergize and cross-regulate during anabolic 
responses remains to be determined. Our experiments show that rapamycin treatment leads 
only to mild downregulation of c-Myc signature genes and c-Myc protein in selected B cells. 
This is in agreement with prior observations showing that optimal translation of c-Myc 
mRNA in lymphocytes requires mTORC1 (Verbist et al., 2016; West et al., 1998; Yang et 
al., 2013b). However, although rapamycin-sensitive mTORC1 signals are necessary for cell 
growth and clonal expansion, they appear to be dispensable for cell cycle progression in our 
model. Given the strong association between c-Myc and cell cycle (Amati et al., 1998; 
Dominguez-Sola et al., 2007; Obaya et al., 1999), this suggests that the effects of rapamycin 
on clonal expansion are unlikely to be mediated solely by decreased c-Myc activity.
B cells with constitutively high mTORC1 activity due to genetic loss of TSC1 or constitutive 
RagA activation were outcompeted by cells with wild-type mTORC1 activity. This is in 
spite of the fact that B cells lacking Tsc1 are fully competent to form GCs when in the 
absence of competition with WT cells (Ci et al., 2015), ruling out deleterious effects of 
mTORC1 hyperactivation on GC B cell viability. A potential explanation for this 
disadvantage is that the failure of B cells to downregulate mTORC1 in the DZ may lead to 
excessive retention in this compartment and consequently decreased access to antigen and 
Tfh cells in the LZ. This would explain the decreased GC B cell competitiveness as well as 
the impaired affinity maturation in mTOR gain-of-function models, given the tight 
dependence of affinity maturation on the spacing of proliferation and selection cycles 
(Kepler and Perelson, 1993). More broadly, our data are in line with previous reports 
showing that both mice and humans with constitutive hyperactivity of the upstream 
PI3K/Akt pathway show impaired humoral responses (Lucas et al., 2014; Suzuki et al., 
2003), although the relative contribution of mTORC1 vs. other targets of PI3K/Akt (e.g., 
Foxo1) to these phenotypes is unclear.
We therefore propose a model in which dynamic regulation of mTORC1 activity during the 
cyclic re-entry process supports positive selection in the GC. In the LZ, mTORC1 is induced 
in positively selected B cells, promoting an increase in anabolic capacity (manifested as an 
increase in biomass and ribosome content) that supports subsequent proliferation and clonal 
expansion. Although the rapamycin-sensitive arm of mTORC1 does not directly control cell 
cycle progression in these cells, decreases in mTORC1 activity and cell size are closely 
related with cessation of proliferation, likely due to the coordinated induction of a 
proliferative program through c-Myc or other pathways. Our data are also consistent with 
the need for decay in mTORC1 activity as cells proliferate in the DZ. Such decay appears to 
be required for a timely return of B cells from DZ to LZ, and GCs that fail to modulate 
mTORC1 activity are unable to discern cells that have acquired mutations that improve 
affinity, thus disabling affinity maturation.
Finally, to overcome the caveats related to the lack of cellular specificity of a chemical 
inhibitor such as rapamycin, we generated a strain of mice harboring a tumor-derived 
mutation in Mtor that renders the kinase insensitive to the drug. Rescue of the rapamycin 
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phenotype when only transferred B cells carried the MtorF2108L mutation confirmed that 
mTORC1 was required in a B cell-specific manner, rather than acting through other relevant 
cell types that rely on this pathway for differentiation and function, such as Tfh cells (Ray et 
al., 2015; Yang et al., 2016; Zeng et al., 2016). We expect that this chemical-genetics 
approach, and the MtorF2108L mice in particular, will be useful to others to address the roles 
of mTORC1 in other settings, without the kinetic limitations of conditional mouse genetics.
STAR METHODS
Contact for Reagent and Resource Sharing
Further information and requests for reagents and resources should be directed to and will be 
fulfilled by the Lead Contact Gabriel D. Victora (victora@rockefeller.edu). The mouse lines 
obtained from other laboratories are described bellow and may require a Material Transfer 
Agreement (MTA) with the providing scientists. DEC-OVA plasmids were obtained from M. 
Nussenzweig (Rockefeller University, New York, USA) and require an MTA. MtorF2108L 
mice generated in this study are available from our laboratory, also with an MTA.
Experimental Model and Subject Details
Mice—C57BL6/J, B1-8i (Sonoda et al., 1997), PA-GFP (Victora et al., 2010), ECFP-
transgenic (Schaefer et al., 2001) and Tsc1fl/fl (Kwiatkowski et al., 2002) mice were 
purchased from Jackson Labs (Strain numbers 000664, 012642, 022486, 004218, and 
005680 respectively). RragaGTP (Efeyan et al., 2013) and Mtor F2108L mice were generated 
and maintained in our laboratories. Aicdacre (Robbiani et al., 2009), B1-8hi (Shih et al., 
2002), Ly75−/− (Inaba et al., 1995), and LY75-tg (which express human DEC-205 under the 
CD11c promoter) (Kamphorst et al., 2010) mice were originally provided by M. 
Nussenzweig (Rockefeller University, New York, USA). MycGFP mice (Huang et al., 2008) 
were a generated originally by B. Sleckman (Weill Cornell Medicine, New York, USA) and 
were provided to us by R. Dalla-Favera (Columbia University, New York, USA). Cd79acre/+ 
mice (Hobeika et al., 2006) were provided by M. Reth (Max Planck Institute, Freiburg, 
Germany). Because we observed debilitating or lethal off-target effects of Cd79acre/+ 
mediated deletion of Tsc1 in the kidneys, affinity maturation ELISA experiments were 
preformed with bone marrow chimeras in which lethally irradiated wild-type hosts were 
reconstituted with Cd79acre/+.Tsc1fl/fl or Cd79acre/+.Tsc1+/+ bone marrows. All mice were 
housed in groups of 2–5 animals per cage in specific pathogen-free facilities at the 
Whitehead Institute for Biomedical Research and The Rockefeller University. All protocols 
were approved by the Massachusetts Institute of Technology Committee for Animal Care 
and the Rockefeller University Institutional Animal Care and Use Committee. Males and 
females, 6–8 week-old mice were used in the experiments. When adoptive cell transfer was 
performed, host animals were invariably males.
Method Details
Cell transfers, immunizations and treatments—Spleens were macerated, red blood 
cells were lysed with ACK buffer (Lonza), and resulting cell suspensions were filtered 
through a 70 μm mesh into PBS supplemented with 0.5% BSA and 2 mM EDTA (PBE). 
Resting B cells were obtained by magnetic cell separation (MACS) using anti-CD43 beads 
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(Miltenyi), as per manufacturer’s instructions. Percentage of B1-8hi cells was determined by 
flow cytometry after staining a cell aliquot with 5 μg/mL NP19-PE (Biosearch 
Technologies).
To generate GCs, male C57BL/6 recipient mice were first primed intraperitoneally (i.p.) 
with 50 μg OVA absorbed in alum (Imject Alum, Thermo Scientific) at 2:1 v:v ratio in 100 
μL volume, and then boosted two to four weeks later with 25 μg NP(16)-OVA (Biosearch 
Technologies), delivered subcutaneously (s.c.) into the hind footpad. One day prior to 
boosting, B1-8hi B cells of the indicated genotypes were adoptively transferred at the 
proportions depicted in each figure. Where indicated, 6 days after immunization with NP-
OVA, 5 μg of DEC-OVA, produced in our laboratory as described (Pasqual et al., 2015), was 
injected s.c. into the hind footpad. In the experiments described in Fig. 1 (B,E,F) Ly75−/− 
mice were used as recipients, to control for the presence of DEC-205 on host cells. In this 
case, to prevent the rejection of Ly75-expressing cells that is observed in a fraction of 
Ly75−/− host mice approximately one week after adoptive transfer, Ly75−/− hosts were 
further crossed to a transgenic line expressing human DEC-205 (which does not bind DEC-
OVA) under the CD11c promoter (LY75-tg) (Kamphorst et al., 2010). We do not observe 
rejection of Ly75+/+ cells in these hosts (our unpublished data), presumably due to 
tolerization of the immune system to mouse DEC-205 due to presence of the human 
orthologue. Our results using wild-type or Ly75−/− LY75-tg hosts across multiple 
experiments are undistinguishable [compare, for example, (Victora et al., 2010) and 
(Bannard et al., 2016)]; we therefore use wild-type hosts for most experiments. For titration 
of the dose of DEC-OVA (Fig. 1G–H), mice were injected with either 5 μg/footpad of DEC-
OVA or 1 μg of DEC-OVA supplemented with 4 μg of anti DEC-205 antibody fused to the 
irrelevant antigen P. falciparum circumsporozoite protein (DEC-CS) (Boscardin et al., 2006), 
which is required to achieve a quantitative decrease in OVA targeting to DEC205-expressing 
cells (Gitlin et al., 2014). For CD40L blockade experiments (Fig. 1I–J), mice were injected 
intravenously (i.v.) with 200 μg of a CD40L blocking antibody (Clone MR-1, BioXCell) or 
200 μg of Armenian Hamster IgG isotype control (BioXCell) 2 h prior to injection of DEC-
OVA.
Rapamycin was purchased from LC Laboratories and diluted at 10 mg/mL in ethanol. Prior 
to injection, the stock solution was further diluted in PBS and injected i.p. at 2.5 mg/kg at 
the indicated time points. For CD40 activation experiments (Fig.S1E–F), mice were 
immunized with 10 μg/footpad of keyhole limpet hemocyanin (KLH, Sigma) absorbed in 
alum, and, after 10 days, anti-CD40 agonist antibody (Clone FGK4.5, BioXCell) was 
injected s.c. at 25 μg/footpad. To generate polyclonal GCs, mice were immunized s.c. with 
NP(19)-KLH in alum at 2:1 ratio. Skin-draining lymph nodes were harvested 14 days later. 
For ELISA experiments, mice were immunized i.p. with 50 μg of NP(16)-OVA adsorbed in 
alum. For sequencing of primary GCs shown in Figure 7, mice were immunized s.c. with 10 
μg/footpad of NP(16)-OVA adsorbed in alum.
Flow cytometry and cell sorting—Popliteal lymph nodes were harvested, macerated in 
PBE, and filtered through a 70 μm mesh. Single-cell suspensions were incubated for 5 
minutes with 1 μg/mL of anti-CD16/32 (24G2, eBioscience) and then stained on ice for 30 
min in PBE using the reagents listed in the Key Resources Table. Cells were maintained at 
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4°C at all times until acquisition. For phospho-S6 staining, incubation was precisely timed to 
prevent time-related variations in dephosphorylation by endogenous phosphatases. Fixation/
Permeabilization [Cytofix/Cytoperm (BD)] following cell-surface staining was timed to 
happen exactly 30 minutes after euthanasia for each sample. This was followed by staining 
with anti-phospho-S6 diluted in Perm/Wash buffer for 2 h. For cell cycle analysis or staining 
of dsRNA content, fixed and permeabilized cells were stained in Perm/Wash buffer with 10 
μg/mL Hoechst (Invitrogen) for 5 min or 4 μg/mL Pyronin Y (Sigma). Samples were 
acquired on Becton Dickinson Fortessa or LSR-II flow cytometers. For Foxo1 staining, 
nuclear permeabilization was performed per manufacturer instructions using the Foxp3 
Staining Buffer Set (eBioscience) after prior fixation of surface-stained samples in 
paraformaldehyde 2% for 10 min. To detect glucose uptake in vivo, 5 mg/kg of 2-(N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) was injected i.v. 25 min 
prior to lymph node harvesting. Detection of cells in the early S phase of the cell cycle was 
performed using dual nucleotide pulse, as described elsewhere (Gitlin et al., 2014). Briefly, 
mice were injected i.v. with 1 mg of 5-ethynyl-2′-deoxyuridine (EdU) and one hour later 
with 2 mg of 5-bromo-2′-deoxyuridine (BrdU). Lymph nodes were harvested 30 min after 
the second injection. Nucleotide incorporation into DNA was assayed with Click-iT Plus 
EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Invitrogen) and FITC BrdU Flow Kit 
(BD). Cells in early S phase were defined as BrdU+EdU−. Unless otherwise indicated, GC 
cells were gated as live/singlet cells, CD19+, Fashi, and CD38−. For cell sorting, cells were 
stained as above and index-sorted directly into plates containing guanidine thiocyanate 
buffer (Qiagen) supplemented with 1% β-mercaptoethanol using a FACS Aria II (BD). Data 
were analyzed in Flowjo v.8.7 and v.10.0.8. Extraction of single cell Forward Scatter values 
from LZ and DZ gates was performed using the ImmPortFCSConvLogicleTrans tool in 
GenePattern (Broad Institute).
Immunofluorescence—Lymph nodes were harvested and immediately fixed at 4°C in 
PBS containing 4% paraformaldehyde and 10% sucrose for 1 h, followed by overnight 
incubation at 4°C in a solution of 30% sucrose in PBS. Tissues were embedded in optimum 
cutting temperature compound and cut into 20 μm sections using a Leica Cryostat 
Microtome. Sections were fixed in pre-cooled acetone at −20°C for 10 min, and blocked 
with Streptavidin/Biotin Blocking Kit (Vector Laboratories). Samples were stained in four 
steps: (1) rat anti-AID; (2) goat anti-rat Alexa 555; (3) rat anti-CD35 biotin and rabbit anti-
c-Myc; and (4) streptavidin BV421, anti-rabbit Alexa 488 and anti-phospho-S6 Alexa 647. 
The antibodies used are described in Key Resources Table. Incubations were performed in 
PBS containing 5% BSA, 10% normal mouse serum and 0.1% Triton X-114. Sections were 
mounted in Fluoromount-G (SouthernBiotech) and imaged on a Zeiss 700 confocal 
microscope with using a 20 × objective with numerical aperture of 0.8.
RNA-sequencing—Each sample consisted of 200–500 cells sorted from individual mice. 
Data shown in Figs. 1 and S1 are derived from 3 independent biological replicates. Both 
Ly75+/+ and Ly75−/− cells were sorted from the same mice 12 h after DEC-OVA injection, 
totaling 6 paired samples from 3 mice. Data in Fig. S3 are from 4 independent biological 
replicates. Untreated Ly75+/+ and Ly75−/− cells were sorted from the same mice, and 
rapamycin-treated Ly75+/+ cells were from different mice, totaling 12 samples (4 Ly75+/+/
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Ly75−/− untreated pairs and 4 Ly75+/+ treated samples). Rapamycin was given at the time of 
DEC-OVA injection and cells were sorted 24 h after DEC-OVA. Cells were sorted directly 
into guanidine thiocyanate buffer (Qiagen) supplemented with 1% β-mercaptoethanol 
followed by RNA isolation using Agencourt RNAClean XP Beads (Beckman Coulter). RNA 
was then reversely transcribed into cDNA using an oligo(dT) primer and amplified as 
described (Trombetta et al., 2014). Nextera XT was used to prepare a multiplexed pooled 
library of fragmented and uniquely indexed samples for each flow-sorted population. 
Sequencing was performed on an Illumina HiSeq 2500 at the Whitehead Institute Genome 
Technology Core. For analysis, 40-bp single-end reads were pseudo-aligned using Kallisto 
version 0.43.0 against mouse transcriptome (Ensembl GRCm38 – release 79). Gene 
expression was inferred from transcript expression levels using the tximport R package as 
transcripts per million reads (TPM). Enrichment analysis was performed using GSEA 
software v2.2.3 (Broad Institute), with the following settings: 1000 gene set permutations; 
data collapsed to gene symbols using max_probe mode; enrichment statistic = weighted; 
ranking metric = signal2noise. 1 was added to all TPM values to reduce noise from 
transcripts with very low abundance.
Photoactivation—12 h prior to imaging, mice bearing photoactivatable B1-8hi GCs 
received adoptive transfer of 5 × 106 naïve B cells expressing CFP and were injected i.v. 
with Texas Red-conjugated CD35 antibody. For photoactivation, mice were anesthetized 
with 1.5% isoflurane, and popliteal lymph nodes were surgically exposed as described 
previously (Victora et al., 2010). GC DZ were located as areas adjacent to CD35-expressing 
FDCs and devoid of CFP+ naïve B cells, photoactivated in vivo by scanning with a 
multiphoton laser tuned to 850 nm wavelength, and then imaged at 940 nm wavelength. 
Laser power conditions for photoactivation differed slightly according to each GC. To ensure 
that cell viability was maintained after photoactivation, the motility of PAGFP-transgenic 
cells was checked immediately after in vivo photoactivation. After photoactivation, either 
mice were sacrificed immediately (for control lymph-nodes) or incisions were sutured and 
mice were held for 8h and then sacrificed. All imaging experiments were carried out using 
an Olympus BX61WI upright microscope (Olympus 25× 1.05 NA Plan water-immersion 
objective), fitted with a Mai-Tai DeepSee Ti-Sapphire laser (Spectraphysics).
Generation of MtorF2108L mice—Mice were generated by CRISPR/Cas9 gene targeting. 
Cytoplasmic injection of Cas9 mRNA, chimeric sgRNA, and repair oligo into fertilized 
C57BL6 zygotes at the one-cell stage, as described (Wang et al., 2013; Yang et al., 2013). 
Chimeric sgRNA was in vitro transcribed from a synthetic dsDNA template (gBlock, 
Integrated DNA Technologies) using the MEGAshortscript™ T7 Transcription Kit (Thermo 
Fisher Scientific) and purified using Ampure XP beads (Beckman coulter). The repair oligo 
was synthesized as an ssDNA ultramer, PAGE-purified (Integrated DNA Technologies). 
Cas9 mRNA was purchased from Sigma-Aldrich. Sequences used were as follows: dsDNA 
template for chimeric sgRNA transcription (protospacer sequence in capital letters): 
cgctgttaatacgactcactataggGATCTCAAAGCAGCTACCCCgttttagagctagaaatagcaagttaaaataag
gctagtccgttatcaacttgaaaaagtggcaccgagtcggtgctttt.
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Repair oligo (differences from original C57BL6 sequence are in uppercase; mutations 
upstream of the AflII site were for use with a different sgRNA, and were not incorporated 
into the resulting mouse strain): 
tatggccgagatttaatggaggcacaagaatggtgtcgaaagtacatgaagtcggggaacgtcaaAgaTctGacgcaGgcctg
ggacctctactatcacgtCttAagacggatctcTaagcaActGccGcaggtaggctctcgaggcatcctgggttcatctgtgcatc
cagactcgcttctgctggagacttatagaaa.
Assessment of rapamycin resistance—For in vitro experiments, tail fibroblasts were 
obtained by cutting 1 cm tail tip from adult mice, and after a quick rinse in 70% ethanol, 
samples were cut into small pieces with a razor blade, followed by incubation in 1000U 
collagenase type II (Gibco) overnight. The digestion product was filtered through a 100um 
mesh and plated in DMEM with 20% FBS plus antibiotics and fungicides. Rapamycin was 
added to full DMEM at 0.1 nM to 100 nM. For in vivo determination of rapamycin 
resistance, mice were fasted overnight, then given 2.5 mg/kg of rapamycin i.p. or left 
untreated, and 30 min later, refed with normal mouse chow ad libitum for 45 min, and then 
euthanized for organ harvesting. Tissues were harvested and immediately snap-frozen in dry 
ice.
Immunoblotting—Reagents were obtained from the following sources: anti phospho-
T389 S6K1, phospho-S240/244 S6, phospho-T37/T46 4E-BP1, phosho-T308 Akt, phospho-
S473 Akt, total Akt, S6K1, 4E-BP1, S6 and mTOR from Cell Signaling Technology; anti 
From Cell Signaling Technology; anti wing sources: anti phospho-T389 S6K1. Frozen 
samples were lysed in ice-cold lysis buffer (50 mM HEPES (pH 7.4), 40 mM NaCl, 2 mM 
EDTA, 1.5 mM sodium orthovanadate, 50 mM NaF, 10 mM pyrophosphate, 10 mM 
glycerophosphate and 1% Triton X-100, and one tablet of EDTA-free complete protease 
inhibitors (Roche) per 25 mL). Cell lysates were cleared by centrifugation at 15,000 g for 10 
min. Proteins extracts were denatured by the addition of sample buffer, boiled for 5 min, 
resolved by SDS–polyacrylamide gel electrophoresis and analyzed by immunoblotting.
Fetal liver and bone marrow chimeras—WT recipient mice were lethally irradiated 
with 900 Rads. Fetuses were harvested on days 13–16 of pregnancy. Livers were excised and 
macerated using a 70 μm cell strainer in sterile PBS supplemented with 0.5% BSA and 2 
mM EDTA (PBE). 1–10 × 107 total fetal liver cells were transferred into irradiated 
recipients, which were then held for at least 8 weeks to allow hematopoietic reconstitution. 
Septra antibiotics were provided in drinking water for the first 8 weeks after reconstitution. 
Bone marrow chimeras were generated using a similar protocol, except that hematopoietic 
cells were harvested from femurs and tibiae by flushing with PBE.
ELISA—High-affinity and total NP-specific antibodies were measured by ELISA using 10 
μg/ml of NP(2)-BSA or NP(24)-BSA as the coating reagent, respectively. Serum was 
assayed in 3-fold dilutions starting at 1/100. NP-specific IgG1 was detected using goat anti–
mouse IgG1 Fc-specific antibody conjugated to horseradish peroxidase and developed with 
tetramethylbenzidine (Sigma). OD450 was measured using a VERSAmax microplate reader 
(Molecular Devices). Titers were calculated by logarithmic interpolation of the dilutions 
with readings immediately above and immediately below an OD450 of 0.2 (for example, if 
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OD450 readings at dilution 2 (1/900) = 0.3 and at dilution 3 (1/2700) = 0.1, then Titer = 
dilution = 2.5 = 1/1558.
Assessment of VH mutations—Single GC B cells were sorted, RNA was isolated and 
cDNA was transcribed as described for RNA-seq. VH186.2 genes were sequenced and the 
number of total mutations per cell, including the W33L mutation conferring high affinity for 
NP (Allen et al., 1988) was determined. Sequences from B1-8i cells were distinguished from 
endogenous cells bearing the same or similar rearrangements based on the silent T>C 
mutation present in codon 92 of B1-8i but not in wild-type VH186.2 (Sonoda et al., 1997), 
which was not included in the SHM count.
Quantification and Statistical Analysis: The exact values of n indicating the total number 
of animals per group, as well as the definition of center, dispersion and precision measures 
are reported in each Figure and Figure Legend. In Figures 1–2 and 4–6, individual values for 
each animal are plotted and bars represent the mean of each group. In Figure 3D, individual 
values for each cell are plotted and bars represent the mean of each germinal center. In 
Figure 3E, the mean of each germinal center from a different mouse is plotted. In Figure 7, 
the mean of each group of mice ± SEM is shown. Student t test or χ2 test with Yates 
correction were performed as depicted in the Figures. Asterisks indicate statistical 
significance (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; n.s. non-significant). 
Analyses were carried out using Prism software v. 7.0 (GraphPad).
Data and Software Availability
Data Resources—Raw and processed data files for the RNA sequencing analysis have 
been deposited in the NCBI Gene Expression Omnibus under accession number GEO: 
GSE98778.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. GC B cells activate mTORC1 upon positive selection
(A) Experimental setup for RNA-seq of Ly75+/+ GC B cells following forced positive 
selection using DEC-OVA. Host mice were Ly75−/−.LY75-tg in panels (B,E,F) and wild-type 
C57BL6 in panels (G–J) (see STAR Methods). (B) Enrichment of gene signatures related to 
activation of the mTORC1 pathway in LZ Ly75+/+ GC B cells 12 h after DEC-OVA 
injection. Number in top-right corner is the enrichment score; all p-values and FDRs = 0 
(below detection). (C) Immunofluorescence showing c-Myc and phospho-S6 in LZ and DZ 
cells from popliteal lymph node GCs 14 days after footpad immunization with NP-KLH in 
alum. Scale bar, 50 μm. (D) Phospho-S6 staining in c-Myc-positive and negative GC B cells 
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from popliteal lymph nodes of MycGFP/GFP reporter mice 12 days after footpad 
immunization with KLH in alum. GFP fluorescence in GC B cells from a wild-type C57BL6 
is shown as a control. (E–F) Phospho-S6 staining in LZ and DZ cells at the indicated time 
points after DEC-OVA-targeted positive selection of Ly75+/+ GC B cells, following the setup 
depicted in (A). (G–H) Phospho-S6 staining in Ly75+/+ GC B cells after positive selection 
using different doses of DEC-OVA or at different proportions of Ly75+/+ B1-8hi B cells in 
the adoptive transfer (5% vs. 25%). (I–J) Phospho-S6 staining in Ly75+/+ GC B cells 
following blockade of CD40L. Mice were injected intravenously with 200 μg of a blocking 
antibody to CD40L (clone MR-1) or a matched isotype control 2 h prior to DEC-OVA. 
Samples in panels (G–J) were analyzed 12 h after DEC-OVA. *** p<0.001, unpaired 
Student t test. Bars indicate mean ± SEM. All data are from at least two independent 
experiments. (B, n=3; C, n=3; D, n=4; E–F, n=5–6; G–H, n=3–4; I–J, n=3) See also Figure 
S1.
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Figure 2. mTORC1 activation in GC B cells leads to ribosomal biogenesis and cell growth
(A) Forward scatter and Pyronin Y staining (dsRNA content) in Ly75+/+ and Ly75−/− GC B 
cells 36 h after DEC-OVA injection. (B) Glucose uptake in vivo by Ly75+/+ and Ly75−/− GC 
B cells, 24 h after DEC-OVA injection, with or without injection of rapamycin at 6 h after 
DEC-OVA. Measured by intravenous injection of 5 mg/kg of 2-(N-(7-nitrobenz-2-oxa-1,3-
diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) 25 min prior to organ harvesting. (C–D) 
Pyronin Y staining and forward scatter of Ly75+/+ cells 36 h after DEC-OVA injection, with 
or without treatment with rapamycin 12 h after DEC-OVA. (E–H) Kinetics of forward 
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scatter, S6 phosphorylation, Pyronin Y staining, expansion of Ly75+/+ cells (Ly75+/+/
Ly75−/− ratio) and Ly75+/+ DZ/LZ ratio following DEC-OVA injection. * p<0.05, **p<0.01, 
unpaired Student t test. Bars indicate mean ± SD. Data pooled from at least two independent 
experiments. (A, n=6; B, n=3; C–D, n=6; E–H, n=4–7). See also Figure S2.
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Figure 3. Decreased cell size correlates with return from DZ to LZ
(A–B) Experimental setup for assessment of migration of early DZ to LZ emigrants by flow 
cytometry. (C) Representative plots showing photoactivated cells in DZ (red gates) and LZ 
(blue gates) at 0 h or 8 h after photoactivation. (D) Forward scatter of individual cells in DZ 
and LZ 8 h after photoactivation of single GCs. Dashed lines indicate the average cell size of 
Ly75−/− GC B cells from the same GC. Bars indicate mean. (E) DZ and LZ cell size average 
from each GC. *p<0.05, **p<0.01, ***p<0.001, unpaired Student t test. Each GC is from a 
different mouse in three independent experiments (n=3).
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Figure 4. mTORC1-induced cell growth is required for expansion and accumulation in DZ of 
positively selected B cells
(A–B) Experimental setup for DEC-OVA-induced positive selection of Ly75+/+ GC B cells 
followed by mTORC1 inhibition using rapamycin before, midway through, or after cell 
growth and LZ to DZ migration. Clonal expansion (C–D), DZ accumulation (E–F), Foxo1 
upregulation (G), DNA content (Hoechst) (H–I), and S-phase entry (J) among Ly75+/+ GC 
B cells upon treatment with rapamycin at the indicated timepoints after DEC-OVA injection. 
S phase entry (J) is measured by sequential injection of EdU followed by BrdU 1 h later. 
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Cells in early S phase are positive for BrdU only (see STAR Methods). *p<0.05, **p<0.01, 
****p<0.0001, n.s. non-significant, unpaired Student t test, compared to rapamycin-
untreated group. Bars indicate mean. Data pooled from at least two independent 
experiments. (C, n=8; D, n=6; E, n=8; F, n=4; G, n=3; H, n=6; I, n=4; J, n=3). See also 
Figure S3.
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Figure 5. B cell-intrinsic role of mTORC1 in GC selection
(A) CRISPR/Cas9 gene targeting strategy for generating mice carrying F2108L mutation in 
Mtor. (B) Immunoblots from tail fibroblasts from Mtor+/+ and MtorF2108L/+ animals cultured 
in presence and absence of rapamycin. (C) Rapamycin-resistant hosts received adoptive 
transfer of B1-8hi L75+/+.Mtor+/+ B cells for targeted selection in GCs by DEC-OVA 
injection 12 h prior to rapamycin treatment (see Fig. S5A). (D) Phospho-S6 staining in 
transferred L75+/+.Mtor+/+ and host Ly75+/+.MtorF2108L/F2108L GC B cells. (E) Ly75+/+/
Ly75−/− ratio and (F) DZ/LZ ratio in Ly75+/+.Mtor+/+ GC B cells. (G) Wild-type hosts 
received adoptive transfer of B1-8hi Ly75+/+.Mtor+/+ or B1-8hi L75+/+.MtorF2108L/F2108L B 
cells for targeted selection in GCs by DEC-OVA injection 12 h prior to rapamycin treatment 
(see Fig. S5E). (H) Phospho-S6 staining of transferred Ly75+/+.Mtor+/+ or 
Ly75+/+.Mtor F2108L/F2108L cells treated or not with rapamycin. (I) Ly75+/+/Ly75−/− ratio, 
and (J) DZ/LZ ratio of transferred Ly75+/+ cells in GCs. (K) Phospho-S6 staining in Tfh 
cells (CXCR5+ PD-1hi) from MtorF2108L/F2108L [see panel (C)] and Mtor+/+ [see panel (D)] 
mice treated or not with rapamycin. Note that Tfh cells from Mtor F2108L/F2108L mice are 
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fully resistant to rapamycin. (C–F) *p<0.05, **p<0.01, ****p<0.0001, unpaired Student t 
test. Bars indicate mean. Data pooled from at least two independent experiments. (C–F, 
n=2–3; G–J, n=7–9; K n=2–9) See also Figures S4–5.
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Figure 6. Hyperactivation of mTORC1 imposes DZ confinement and a competitive disadvantage 
on GC B cells
(A) Experimental setup for induction of GCs containing mixtures of B1-8hi cells sufficient 
and deficient in Tsc1 upon AID-mediated deletion. (B) Phospho-S6 in GC B1-8hi cells 10 
days after NP-OVA immunization. (C) DZ and LZ staining in GC B1-8hi cells 10 days after 
NP-OVA immunization, quantified over time in (D). (E) Relative percentage (normalized to 
day 7 after immunization) of Tsc1 deficient GC B cells at the indicated time points after NP-
OVA injection. (F) Experimental setup for induction of GCs containing mixtures of B1-8i 
cells carrying Rraga+/+ and RragaGTP/GTP. (G–J) As in (B–E) but using RragaGTP/GTP as an 
mTORC1 gain-of-function allele. B cell donors were either full-body mutant mice or bone 
marrow chimeras (see STAR Methods). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 
unpaired Student t test. Bars indicate mean. Data pooled from at least two independent 
experiments. (A–E, n=4–5; F–J, n=3)
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Figure 7. mTORC1 hyperactivation impairs affinity maturation
Cd79acre/+.Tsc1+/+ and Cd79acre/+.Tsc1fl/fl bone marrow chimeras (see STAR Methods) 
were immunized i.p. with 50 μg of NP-OVA and serum was obtained at the indicated 
timepoints post-immuization. (A) Titers of total (NP24-binding) and high-affinity (NP2-
binding) antibodies and (B) NP2/NP24 titer ratio in these mice. (C–D) as in (A–B) but using 
Rraga+/+ and RragaGTP/GTP fetal liver chimeras. (E) Total number of VH mutations and (F) 
number of W33L high-affinity mutations in single-cell sorted GC B cells from wild type 
mice adoptively transferred with B1-8i Rraga+/+ or B1-8i RragaGTP/GTP B cells, obtained 
from popliteal lymph nodes harvested 12 days after immunization with NP-OVA. Data 
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pooled from two independent experiments. *p<0.05, **p<0.01, ****p<0.0001, n.s. non-
significant, unpaired Student t test. In A–D, bars indicate mean ± SEM; in E bars indicate 
mean. (A–B, n=8–9; C–D, n=8; E–F, n=2)
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